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Abstract
Background: Although feeding intolerance is a common complication in trauma patients, the incidence, development, and effects
are poorly understood. Methods: We performed a retrospective study in which trauma patients were classified as having feeding
intolerance based on time to reach feeding goal. Subsequently, we sorted patients by gastric residual volumes (GRVs) or symptoms
of slowed gastrointestinal motility. Results: One-third of trauma patients experienced delayed time to reach feeding goal after
diet initiation. Delayed feeding was associated with prolonged intensive care unit (ICU) stays, increased readmission rates, and
increased incidence of sepsis. Patients with elevated GRV (>500 mL) had significantly prolonged ICU and hospital stays and
increase incidence of sepsis. Patients with >2 symptoms of slowed gastrointestinal motility had prolonged ICU and hospital stays,
delayed time to reach feeding goals, significantly increased readmission rates, increased incidence of infectious and thromboembolic
complications and sepsis, decreased serum prealbumin levels, and increased CRP levels. Conclusion: Decreased gastrointestinal
motility in trauma patients is associated with worse outcomes and increased systemic inflammation. (JPEN J Parenter Enteral
Nutr. 2019;43:742–749)
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Clinical Relevancy Statement
A retrospective study was conducted to assess the incidence
and associated complications of feeding intolerance after
trauma. Approximately one-third of moderately to severely
injured trauma patients developed feeding intolerance, re-
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sulting in prolonged intensive care unit stays, increased
infectious and thromboembolic complications, and higher
readmission rates. Increased symptoms of slowed gastroin-
testinal motility were associated with increased markers of
inflammation.
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Background
Feeding intolerance (FI) is a common complication in
trauma patients. Although several publications address FI
in specific patient subpopulations, including traumatic head
injury and abdominal trauma patients,1,2 few publications
address FI in the general trauma patient population. Fur-
thermore, while FI has been widely studied in surgical
patients,3-6 the development and effects of FI in trauma
patients are poorly understood. Surgical patients are often
in controlled environments and can be pretreated to avoid
FI; however, trauma patients cannot be pretreated and often
suffer from multiple injuries which complicate treatments.
Thus, the approach to treating FI in trauma patients may
be different than in other surgical patients.
The significance of FI is highlighted by the benefits
of early enteral nutrition (EN). In critically ill patients,
adequate EN within the first 48 hours of hospital ad-
mission decreases hospital length of stay (LOS), reduces
thrombotic and infectious complications, and lowers all-
cause mortality.2,7,8 These benefits are especially appar-
ent in trauma patients, whose severe injuries result in
hypermetabolic and hypercatabolic states, increasing their
need for nutrition beyond that of a physiologically normal
individual.9 Early EN has become a central part of the
critical care paradigm. However, the development of FI can
prevent early enteral feeding.
Inflammation is a key contributor to the development
of postoperative ileus (POI), according to studies in ani-
mal models and patients.10,11 Tissue macrophage and mast
cell activation lead to secretion of inflammatory cytokines
and recruitment of leukocytes into the intestinal muscu-
laris, resulting in smooth muscle dysfunction.10,11 However,
whether the same mechanism occurs in trauma patients, or
non-abdominal surgical patients for that matter, remains
unclear. Most trauma patients have systemic inflammation
due to their injuries; however, the association between
inflammation and FI is unclear.
The purpose of the present study is to gain a better
understanding of the incidence, development, and effects of
FI in trauma patients. To achieve this goal, we performed
a retrospective study of trauma patients. For the purpose
of the present study, we defined FI as a delay (3 days)
in reaching feeding goal after diet initiation. Subsequently,
we categorized patients based on gastric residual volume
(GRV) only or multiple symptoms of slowed gastrointesti-
nal motility. We hypothesized that FI in trauma patients
would be associated with adverse outcomes.
Methods
A retrospective analysis of prospectively collected data was
performed. All data came from an institutional review
board–approved study of patients admitted to the Hous-
ton Hermann Memorial Level 1 trauma center, Houston,
Texas, in 2012 and 2013. Data were retrospectively collected
from the medical records of 202 adult trauma patients
(>18 years) having3 days of intensive care unit (ICU) stay.
Patients with missing feeding data (55 patients), including
patients who transitioned to oral feeding within the first
3 days after admission, were excluded from study; thus,
data from 147 patients were analyzed. Trauma included
blunt, penetrating, and burn injuries. The following data
were collected: age, sex, race, body mass index (BMI), mode
of injury (burn, blunt, or penetrating), injury severity scores
(ISS) and body region abbreviated injury scales (AIS),
laparotomy, diagnosis of ileus, hospital LOS, and ICULOS.
Diagnosis of ileus was confirmed radiographically (abdom-
inal x-ray including kidneys, ureters, and bladder). To assess
inflammatory state, we recorded serum prealbumin and C-
reactive protein (CRP) levels measured within the first week
after admission. Neutrophil, macrophage, lymphocyte, and
eosinophil numbers on day 3 after admittance were also
recorded. We recorded the following drug administration:
opioids, metoclopramide, erythromycin, and neostigmine.
Morphine equivalents (opioids only) were calculated using
the following equation: morphine equivalents = [(mor-
phine) + (hydromorphine × 4) + (oxycodone × 1.5) +
(fentanyl × 2.4) × (hydrocodone)]/LOS. Outcomes, which
included LOS in ICU and hospital (for initial trauma-
related hospital admittance), readmission within 1 year
of discharge, sepsis, infectious and thrombotic complica-
tions (during hospital stay), and in-hospital mortality, were
recorded. To assess gastrointestinal motility, we recorded
nausea (on 2 consecutive days), vomiting, abdominal dis-
tension (on 2 consecutive days), constipation, highest GRV
over 4 hours during ICU stay, and diagnosis of ileus.We also
recorded feeding goals (as set by the hospital nutritionist)
and time to reach feeding goals (time after feeding initiation
to reach feeding goal). Energy deficits and protein deficits
in the ICU were recorded. Use of parenteral nutrition (PN)
was also recorded.
Comparisons between groups were performed using
a t-test. Analysis via χ2was used for comparison of
categoric data. Power analysis was used to determine if the
patient number was adequate. Effect size was determined
using Hedges’ g with the following effect size calculator:
https://www.polyu.edu.hk/mm/effectsizefaqs/calculator/
calculator.html.12
Results
All Patients
Data are reported for 147 patients. Patients were catego-
rized based on time to reach feeding goal as follows: FI
3 days, or no FI (NFI) <3 days (Table 1). Based on this
classification, 33% of trauma patients developed FI. No
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Table 1. All Patients.
Category NFI FI P
Number of patients (% of total) 98 (67.7) 49 (33.3)
Age (years) 43.9 ± 1.7 38.8 ± 2.1 .074
Male sex (% within group) 70 (71.4) 38 (77.6) .43
BMI 28.6 ± 0.7 28.0 ± 0.9 .62
Race: White 49 (50.0%) 25 (51.0%) .72
Hispanic 26 (26.5%) 15 (30.6%)
Black 14 (14.3%) 7 (14.3%)
Other 9 (9.2%) 2 (4.1%)
ISS (median) 23.6 ± 1.1 (22) 26.0 ± 1.9 (24) .23
Abd AIS (% patients with AIS 4) 1.1 ± 0.2 (14.3) 1.6 ± 0.3 (18.4) .12 (.52)
Laparotomy 25 (25.5%) 21 (42.9%) .032
MOI: Blunt 70 (71.4%) 35 (71.4%) 1.00
Penetrating 14 (14.3%) 7 (14.3%)
Burn 14 (14.3%) 7 (14.3%)
Ileus (% within group) 19 (19.4) 20 (40.8) .006
Abdominal distension (% within group) 46 (46.9) 30 (61.2) .10
Nausea (% within group) 12 (12.2) 8 (16.3) .50
Vomiting (% within group) 28 (28.6) 19 (38.8) .21
Constipation (% within group) 37 (37.8) 26 (53.1) .077
GRV (mL) 499.6 ± 39.7 700.8 ± 75.5 .010
Slowed GI motility symptoms, total 1.9 ± 0.1 2.8 ± 0.2 .002
Morphine equivalents (average/day) 82.0 ± 16.0 71.3 ± 16.6 .67
Treated w/prokinetics (% within group) 35 (35.7) 31 (63.3) .002
LOS (days) 24.0 ± 1.8 29.6 ± 2.3 .074
ICU (days) 11.2 ± 0.9 16.7 ± 1.5 .001
Time to feeding goal (days) 1.2 ± 0.06 5.3 ± 0.4 <.001
Mortality (% within group) 13 (13.3) 4 (8.2) .36
Readmission (% within group) 24 (28.6) 21 (46.7) .040
Infection complications (% within group) 54 (55.1) 30 (61.2) .48
Thromboembolic complications (% within group) 16 (16.3) 12 (24.5) .23
Sepsis (% within group) 21 (21.4) 21 (42.9) .007
Data are listed as mean ± standard error, except where % or median are indicated. P-values in bold indicate significant differences.
Abd AIS, abdominal abbreviated injury scale; FI, feeding intolerance; GI, gastrointestinal; GRV, gastric residual value; NFI, no feeding
intolerance; ICU, length of intensive care unit stay; ISS, injury severity score; LOS, length of hospital stay; MOI, mode of injury; w/, with.
differences in sex, BMI, or race were detected; however, age
tended to be younger in the FI group compared with the
NFI group (P = .074).
ISS (P = .23), abdominal AIS (P = .12), and incidence
of severe abdominal AIS (P = .52) were not significantly
different; however, the FI group had more laparotomies
(P = .032) (Table 1). We detected no differences in any
other regional AIS (data not shown). Of note, a majority
of patients were severely injured; 79.6% and 81.6% of
patients in the NFI and FI groups, respectively, had ISS
scores 16, with no significant differences between groups
(P= .77).13 The distribution of injury mode, predominantly
blunt injury, was similar between groups.
More patients were diagnosed with ileus in the FI
group (40.8%) compared with the NFI group (19.4%,
P = .006; Table 1). The incidence of other symptoms of
slowed motility (abdominal distension, nausea, vomiting,
and constipation) were not statistically different between the
2 groups; however, GRV was significantly increased in the
FI group. Furthermore, the total number of symptoms of
slowed GI motility, which included abdominal distension,
nausea, vomiting, constipation, ileus, and GRV >500, was
increased significantly in the FI group compared with the
NFI group (P = .002).
The use of morphine did not differ between the
groups (P = .58). Significantly more patients in
the FI group received prokinetics (metoclopramide
and/or erythromycin), compared with the NFI group
(64.0% vs 34.9%, P = .001). No patients received
neostigmine.
ICU stays were significantly longer in the FI group
compared with the NFI group (P = <.001), but hospital
LOS was not significantly different (P = .074). Mortality
was not significantly different between the groups; however,
readmission rates were significantly higher in patients with
FI (P = .040). No differences in infectious or thromboem-
bolic complications between the 2 groupswere observed, but
more patients developed sepsis in the FI group (P = .007).
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Table 2. GRV vs GI Symptoms.
Category
GRV
500 mL
GRV
>500 mL P
2 GI
symptoms
>2 GI
symptoms P
Number of patients (% of total) 80 (54.4) 67 (45.6) 88 (59.9) 59 (40.1)
ISS 22.2 ± 1.2 27.0 ± 1.5 .014 23.1 ± 1.2 26.3 ± 1.5 .11
Abd AIS 0.94 ± 0.16 1.66 ± 0.20003 .009 1.06 ±0.16 1.58 ± 0.24 .07
Laparotomy 18 (22.5%) 28 (41.8%) .012 19 (21.6%) 27 (55.1%) .002
LOS (days) 22.6 ± 1.9 30.0 ± 2.2 .012 20.9 ± 1.4 33.9 ± 2.6 <.001
ICU (days) 11.1 ± 0.9 15.5 ± 1.3 .006 10.6 ± 0.7 17.2 ± 3.6 <.001
Time to feeding goal (days) 2.4 ± 0.3 2.9 ± 0.3 .30 2.2 ± 0.2 3.2 ± 0.4 .023
Mortality (% within group) 11 (13.7) 7 (10.4) .54 14 (15.9) 4 (8.2) .098
Readmission (% within group) 19 (27.5) 50 (60.2) .06 18 (24.3) 28 (50.9) .002
Infection comp. (% within group) 43 (53.8) 42 (62.7) .27 45 (51.1) 40 (67.8) .045
Thromboembolic comp.
(% within group)
13 (6.2) 15 (22.4) .35 12 (13.6) 16 (32.7) .041
Sepsis (% within group) 17 (21.2) 25 (37.3) .032 16 (18.2) 25 (51.0) <.001
Total energy deficits in ICU −11,429.8 ± 1329.1−14,381.3 ± 1991.0 .22 −9617.9 ± 909.6 −17,217.1 ± 2390.3 .0014
Total protein deficits in ICU −704.9 ± 107.6 −1313.1 ± 482.5 .19 −568.7 ± 57.0 −1566.2 ± 539.3 .034
PN 6 (7.5%) 15 (22.4%) .010 6 (6.8%) 15 (25.4%) .006
Serum prealbumin (mg/dL) 10.8 ± 0.7 10.4 ± 0.6 .75 11.7 ± 0.6 9.1 ± 0.5 .016
CRP (mg/dL) 138.0 ± 5.4 156.2 ± 5.9 .056 140.7 ± 5.0 158.3 ± 4.7 .07
Monocytes (%) 7.0 ± 0.3 7.3 ± 0.4 .52 6.5 ± 0.3 8.1 ± 0.4 .003
Data are listed as mean ± standard error, except where % or median are indicated. P-values in bold indicate significant differences.
Abd AIS, abdominal abbreviated injury scale; comp., complications; CRP, C-reactive protein; GI, gastrointestinal; GRV, gastric residual value;
ICU, length of intensive care unit stay; ISS, injury severity score; LOS, length of stay; PN, parenteral nutrition.
Comparison of Outcomes Based on GRV vs
Symptoms of Slowed Motility
FI is diagnosed at most hospitals based on high GRV; how-
ever, symptoms of slowedGImotility were also significantly
different in the FI group compared with the NFI group
(Table 1). To determine if consideration of GI symptoms
is important in the outcomes of FI, we compared trauma
patients based on sorting by either GRV or by symptoms
of slowed GI motility (Table 2). In the first comparison,
patients were sorted into 2 groups depending on GRV:
patients who always had GRVs 500 mL or patients
who developed GRVs >500 mL. Despite ISS, abdominal
AIS, and laparotomy incidence being significantly higher
in the GRV >500L group, time to feeding goal was not
significantly different between the groups (P = .30). The
group with GRV >500mL had longer hospital and ICU
stays (P = .012 and .006, respectively). However, outcomes,
including readmission and infectious and thromboembolic
complications, were not significantly different between the
2 groups (P = .06, .27, and .35, respectively). The incidence
of sepsis was significantly higher in the GRV >500 mL
group compared with the lower GRV group (P = .032).
Energy and protein deficits were not significantly different
between the 2 GRV groups (P = .22 and .19, respectively);
however, significantly more patients in the higher GRV
group received PN. Markers of inflammation, including
serum prealbumin and circulating monocytes, were not
significantly different between the 2 GRV groups (P = .75
and .52, respectively); however, CRP tended to be higher in
patients with higher GRV (P = .056).
To compare patients based on symptoms of slowed GI
motility, patients were sorted into 2 groups: patients with
2 symptoms of slowed GI motility and patients with >2
symptoms of slowed GI motility (Table 2). Symptoms of
slowed GI motility included abdominal distension, nausea,
vomiting, constipation, GRV >500 mL, or ileus. ISS and
abdominal AIS were not significantly different between the
2 groups (P = .11 and .07, respectively). The group with
more symptoms of slowed GI motility had significantly
more laparotomies compared with the group with fewer
symptoms. LOS and ICU stays were significantly longer in
the group with more GI symptoms (P < .001 for both).
The group with more symptoms of slowed GI motility
had significantly more complications, including infectious
and thromboembolic complications (P = .045 and .041,
respectively) and sepsis (P < .001), and a significantly
higher incidence of hospital readmissions within 1 year of
the trauma (P = .002). Time to reach feeding goal was
significantly longer in patients with more symptoms of
slowed GI motility (P = .023), and both energy deficits
and proteins deficits (P = .0014 and .034, respectively)
were significantly higher in the group with >2 symp-
toms of slowed GI motility. Significantly more patients in
the group with >2 symptoms of slowed GI motility re-
ceived PN. Interestingly, markers for inflammation changed
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Table 3. Correlation of GRV and GI Symptoms With Feeding Intolerance Measures.
GRV GI Symptoms
Category R2 P
Effects Size
(Hedges’ g) R2 P
Effects Size
(Hedges’ g)
Time to feeding goal 0.18 .027 0.21 0.24 .003 0.39
Energy deficit in ICU 0.17 .045 0.21 0.30 <.001 0.57
GI, gastrointestinal; GRV, gastric residual volume; ICU, intensive care unit.
significantly in patients with increased symptoms of slowed
GI motility, including significantly lower serum prealbumin
and increased circulating monocytes (P = .016 and .003,
respectively). CRP tended to be higher in the group with
more symptoms of slowedGImotility (P= .07). There were
no significant differences in neutrophils or lymphocytes.
Associations between measures of FI (time to feeding
goal and energy deficit) and predictors of FI (GRV and
symptoms of slowed GI motility) were evaluated (Table 3).
The correlation coefficients for GRV vs time to feeding goal
or energy deficit were significant but very low (P = .027
and .045, R = 0.18 and 0.17, respectively). GI symptoms
also correlated significantly with time to feeding goal or
energy deficit (P = .003 and P < .001, respectively); the
correlation coefficients for these correlations were also low,
but higher than GRV (R = 0.24 and 0.30, respectively). The
effect size on feeding goal or energy deficits were higher
when patients were sorted based onGI symptoms vs sorting
byGRV (Hedges’g= 0.39 and 0.57 vs 0.21 and 0.21 for time
to feeding goal and energy deficit, respectively).
Effects of Ileus in ISS-Matched Patients
As shown in Table 4, patients with ileus were compared
with patients with no signs of ileus (1 symptom of slowed
motility). Patients with ileus had significantly higher ISS;
therefore, patients were matched, according to ISS, so that
the effects of ileus could be determined independent of the
effects of more severe injury (ISS,P= .98). Not surprisingly,
abdominal AIS and laparotomies were significantly higher
in patients with ileus vs patients with no ileus (P = .011
and < .001, respectively). Hospital LOS were significantly
higher in patients with ileus (P= .0018) and ICU stays were
>doubled in patients with ileus (7.6 vs 15.8 days, P <.001).
The number of symptoms of slowed GI motility was >7
times higher in patients with ileus compared with patients
with no ileus (0.43± 0.10 vs 3.43± 0.24, P< .001). Patients
with ileus also had significantly higher GRVs (P < .001).
As far as indicators of FI, time to reach feeding goal
was significantly prolonged in patients with ileus (P= .017).
Both energy deficits and protein deficits were significantly
higher in patients with ileus compared with patients with no
ileus (P = .031 and .042, respectively).
Infectious and thromboembolic complications were not
significantly different in patients with vs without ileus.
However, the incidence of sepsis and hospital readmission
rates were significantly higher in patients with ileus (P =
.004 andP= .032, respectively). Average serum prealbumin,
measured within the first week after admission, was signif-
icantly lower in patients with ileus compared with patients
with no ileus (P = .03), and CRP was significantly higher
in patients with ileus (P = .016). Monocytes did not differ
significantly between the 2 groups. Interestingly, the number
of circulating lymphocytes was significantly lower in the
ileus group compared with patients with no ileus (P = .01).
Effects of Prokinetic Treatment in Ileus
Patients
As shown in Table 5, only 7 patients with ileus were not
treated with prokinetics. The ISS and abdominal AIS were
not significantly different between the untreated and treated
groups. Despite prokinetic treatment, hospital and ICU
LOSwere significantly longer in the treated group compared
with the untreated group (P = .04 and .007, respectively).
Time to feeding goal and energy and protein deficits in
the ICU were not improved with treatment. GRV and
symptoms of slowed GI motility were significantly higher
in the treatment group compared with the untreated group
(P = .045 and .002, respectively).
Discussion
We examined the incidence of FI in adult, moderately to
severely injured trauma patients, with 3 days of ICU
stay, including all types of trauma: penetrating, blunt,
and burns. FI was defined as 3 days to reach feeding
goal after diet initiation, based on the recommendation for
early enteral feeding within 24–48 hours.6,14 According to
our results, almost 33% of trauma patients took 3 days
or longer to reach feeding goal. Overall, 26% of trauma
patients were diagnosed with ileus (Table 1). In addition,
40% of trauma patients in this study had >2 symptoms
of slowed GI motility, including nausea, vomiting, abdomi-
nal distension, constipation, diagnosed ileus, and elevated
GRV. Taken together, these results demonstrate the high
percentage of trauma patients that suffer from perturbed
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Table 4. Effects of Ileus, ISS Matched.
Category No Ileus Ileus P
Number of
patients
28 28
ISS 20.5 ± 1.1 20.5 ± 1.3 .98
Abd AIS 0.50 ± 0.17 1.46 ± 0.33 .011
Laparotomy 2 (7.1%) 14 (50.0%) <.001
LOS (days) 17.1 ± 2.1 31.2 ± 3.8 .0018
ICU (days) 7.6 ± 0.8 15.8 ± 2.0 <.001
Time to feeding
goal (days)
1.5 ± 0.2 3.1 ± 0.6 .017
GI symptoms 0.43 ± 0.10 3.43 ± 0.24 <.001
GRV (mL) 161.7 ± 22.4 868.9 ± 109.1 <.001
Mortality (%
within group)
5 (17.9) 2 (7.1) .22
Readmission (%
within group)
4 (18.2) 12 (46.2) .032
Infection comp.
(% within
group)
10 (35.7) 15 (53.6) .18
Thromboembolic
comp. (% within
group)
4 (14.3) 10 (35.7) .064
Sepsis (% within
group)
4 (14.3) 14 (50.0) .004
Total energy
deficits in ICU
−8392.3 ±
1411.3
−17,806.1 ±
3776.9
.031
Total protein
deficits in ICU
−558.3 ± 100.1 −1266.6 ±
305.8
.042
Serum prealbumin
(mg/dL)
12.4 ± 1.4 7.6 ± 0.5 .030
CRP (mg/dL) 115.4 ± 11.3 168.4 ± 5.7 .016
Monocytes (%) 7.5 ± 0.5 7.1 ± 0.5 .54
Lymphocytes (×
100/u)
1.1 ± 0.08 0.8 ± 0.08 .01
Data are listed as mean ± standard error, except where % is listed.
P-values in bold indicate significant differences.
Abd AIS, abdominal abbreviated injury scale; comp., complications;
CRP, C-reactive protein; GI, gastrointestinal; GRV, gastric residual
value; ICU, intensive care unit; ISS, injury severity score; LOS, length
of stay.
gastrointestinal motility. The prevalence of FI in critically
ill patients reported in the literature depends on the patient
population and the definition of FI, and ranges from 2%–
75%.3 In patients with abdominal trauma, approximately
50% developed FI, defined as having abdominal distension,
vomiting, diarrhea, or GRV >200mL.2 In critically ill
septic burn patients, 35% developed FI, defined as GRV
between 150–500 mL for 2 consecutive measurements, GRV
>500mL for 1 measurement, or when vomiting occurred.15
Considering that we included patients with and without
abdominal trauma, the incidence of FI in our study is
similar to previous reports.
POI is associated with increased incidence of infec-
tious and thromboembolic complications, as well as patient
discomfort.5,16 POI also delays enteral feeding, leading to
Table 5. Effects of Treatment in Patients With Ileus.
Category Untreated Treated P
Number of
patients
(% of total)
7 (25) 21 (75)
ISS 20.4 ± 2.3 20.5 ± 1.6 .49
Abd AIS 1.3 ± 0.7 1.5 ± 0.4 .38
Time to feeding
goal (days)
2.3 ± 0.6 3.3 ± 0.8 .23
LOS (days) 19.9 ± 3.5 35 ± 4.6 .04
ICU (days) 7.4 ± 1.2 18.7 ± 2.4 .007
GRV 549.3 ± 180.8 975.5 ± 126.0 .045
GI symptoms 2.3 ± 0.4 3.8 ± 0.2 .002
Total energy
deficits in ICU
−13,139.3 ±
3251.3
−19,361.7 ±
4912.9
.24
Total protein
deficits in ICU
−830.7 ± 217.4 −1419.2 ±
401.4
.21
Data are listed as mean ± standard error, except where % is listed.
P-values in bold indicate significant differences.
Abd AIS, abdominal abbreviated injury scale; GI, gastrointestinal;
GRV, gastric residual value; ICU, intensive care unit; ISS, injury
severity score; LOS, length of stay.
prolonged hospital stays and increased healthcare costs.
Patients undergoing abdominal surgery, who were diag-
nosed with and coded for POI, had an average hospital
cost double that of patients who were not coded for POI.17
Total costs attributed to managing POI in the United
States was calculated as $1.46 billion annually.17 FI, in our
study, was associated with significantly prolonged ICU stays
(Table 1) and a higher incidence of sepsis. Although we
did not record patient care costs, we can safely assume that
increased complications and extended ICU and hospital
stays resulted in increased patient care costs, and increased
patient readmission rates indicate that patient quality of life
and patient care costs continued to be impacted, even after
release from the hospital.
FI is often diagnosed in trauma patients based on ele-
vatedGRV,3,18,19 which is used to guide treatment. However,
our results indicate that multiple symptoms of slowed
GI motility may be more closely associated with FI and
worsened outcomes. This is in line with the latest feeding
recommendations in critically ill patients which state that
feeding should not be withheld on the basis of high GRVs
without other signs of FI.14 The correlation coefficients
for the association between GI symptoms and time to
feeding goal or energy deficit are higher than the correlation
coefficient for the relationship between GRV and these
indicators of FI (Table 3). The effect size is also higher
when patients are sorted based on all symptoms of slowed
GI motility rather than elevated GRV alone (Table 3). The
data in Table 2, showing worsened outcomes for patients
with >2 symptoms of slowed GI motility, support the
data in Table 3. Patients with >2 symptoms of slowed
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GI motility took significantly longer to reach feeding goal
and had significantly higher energy and protein deficits
compared with patients with fewer symptoms of slowed
GI motility. In contrast, the patients with higher GRV did
not have significantly worse outcomes. Furthermore, time
to reach feeding goal and energy and protein deficits were
not significantly different in the group with higher GRV.
Use of PN was significantly higher in the elevated GRV
group but not different than the group with 2 symptoms
of slowed GI motility. Thus, the occurrence of multiple
symptoms of slowed GI motility may be a better predictor
of FI and the associated complications than elevated GRV
alone. However, neither sorting method had a very strong
correlation with FI. To successfully test the effects of
new prokinetics, a better method for diagnosing and/or
predicting the development of FI is needed.
According to the results in Table 2, patients with
>2 symptoms of slowed GI motility had significantly
worse outcomes, including significantly more infectious and
thromboembolic complications, significantly higher inci-
dence of sepsis, and significantly higher readmission rates
1 year after hospitalization for trauma. Overall, these data
suggest that slowed GI motility is associated with worsened
outcomes, and these patients would benefit if effective
prokinetic treatment was available.
The overall incidence of ileus in this study was 25.5%
(Table 1, both NFI and FI groups). The effects of ileus
on patient outcomes in the absence of the effects of injury
severity were investigated by matching patients according to
ISS. Not surprisingly, patients with ileus had a significantly
higher number of laparotomies and abdominal AIS scores
(Table 4). These results are in agreement with reported
incidences of ileus, which are particularly high after abdom-
inal surgeries; the incidences are 25%, 10%–15%, and 60%
for colectomies, gynecologic surgeries, and rectal surgeries,
respectively.4,16,20 Ileus is likely a major risk factor for the
development of FI; in our study, patients with ileus were
more likely to develop FI, as evidenced by doubled time
to reach feeding goals and significantly increased energy
and protein deficits in the ICU. The occurrence of ileus
was associated with worsened outcomes including longer
hospital and ICU LOS, and significantly higher incidence
of sepsis and hospital readmission rates.
The cause of FI in trauma patients is unclear. In-
flammation is thought to be a key contributor to the
development of POI after abdominal surgery,10,11 and our
data support this paradigm for FI in trauma patients
also. Serum prealbumin levels were significantly lower and
CRP tended to be higher in patients with >2 symptoms
of slowed GI motility compared with patients with fewer
symptoms (Table 2). Furthermore, circulating monocytes
were increased in patients with >2 symptoms of slowed GI
motility. Ileus was also associated with increased systemic
inflammation as evidenced by significantly lower serum
prealbumin and significantly higher CRP levels. Of note,
about half of patients who developedFI in our study did not
have laparotomies; thus, gut manipulation alone could not
have triggered the activation of tissuemacrophages. Overall,
these data suggest that patients with slowed GI motility
or ileus had increased systemic inflammation. However,
we could only assess the routinely measured parameters
concerning systemic inflammation. Thus, we can make no
definitive conclusions at this time. Despite these limitations,
this study provides a framework for designing and assessing
the appropriateness of both animal models of FI after
traumatic injury and prospective human patient studies. In
addition, understanding the involvement of inflammation in
the development of FI can direct efforts to earlier detection
of gastrointestinal dysfunction. Our previous laboratory
studies suggest that pathologic distension of the gut wall
can increase intestinal dysfunction21,22; early detection and
treatment of slowed intestinal motility may prevent intesti-
nal distension and, thus, be important in attenuating or even
preventing FI.
We examined the effectiveness of pharmacologic treat-
ment in patients with ileus only. Treatment with prokinetics
(metoclopramide and/or erythromycin) did not improve
hospital or ICU LOS. In fact, patients with ileus who were
treated with prokinetics had significantly longer hospital
and ICULOS compared with untreated patients. Indicators
of FI increased in the treated group, including time to
feeding goal and energy and protein deficits. Although some
studies in critically ill patients showed that erythromycin
and metoclopramide are effective in resolving FI,23,24 our
data are consistent with a Cochrane review showing a
consistent lack of effect for erythromycin, and inconsistent
effects of metoclopramide for the treatment of ileus.25
Patients in our study were given 250 mg of erythromycin
and/or 10 mg of metoclopramide every 6 hours. Several
recent studies showed that the effectiveness of erythromycin
disappeared after several days at this dosing regimen, which
may account for the overall lack of effect on outcomes.24,26
Furthermore, prokineticsmay be effective in a patient subset
that we were unable to delineate in our study.
There were several limitations to our study. This was a
retrospective study and, thus, the conclusions are limited.
In addition, we did not differentiate between lack of feeding
due to poor gastrointestinal dysfunction and lack of feeding
due to other causes, such as operating room visits. When
studying the effectiveness of prokinetics, patient numbers
were small, and worse symptoms may have prompted treat-
ment in these patients. Despite these limitations, our data
and other studies suggest that the prokinetics currently
available to treat FI are either ineffective or, at most, only
marginally effective in improving gastrointestinal motility in
trauma patients.
There is a dire need for new and more effective proki-
netics. To develop new prokinetics, a more thorough under-
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standing of how impaired gastrointestinal motility develops
in trauma patients is necessary. Furthermore, the ability
to predict which patients will develop FI is necessary for
new drugs to be successfully tested. GRV or symptoms
of slowed gastrointestinal motility are poor predictors of
FI. A reliable early biomarker, such as an inflammatory
mediator, would be optimal for predicting and treating
patients with compromised gastrointestinal motility be-
fore further damage, such as mucosal dysfunction, occurs.
Effective and early treatment of compromised gastrointesti-
nal motility may improve outcomes in trauma patients.
In summary, we demonstrate that approximately one-
third of trauma patients develop FI. Decreased gastroin-
testinal motility, associated with an elevated inflammatory
response, is associated with worsened outcomes. A better
understanding of the mechanism(s) by which FI in trauma
patients develops is needed to identify new drug targets for
treating FI.
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